Nonetheless, considering the dearth of therapeutic options for COVID-19 and the established safety profile of mGluR5 NAMs, it is worthwhile to test clinical grade mGluR5 NAMs, such as AFQ056, basimglurant and dipraglurant, in in vitro and in vivo models of COVID-19. The gene discussed is GRM5; the disease is COVID-19.